Molecular characterization and prognostic significance of FLT3 in CML progression.

abstract：:Because of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatinib and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without any congenital anoma...

journal_title：Leukemia research

authors： Ali R,Ozkalemkaş F,Ozçelik T,Ozkocaman V,Ozan U,Kimya Y,Köksal N,Gülten T,Yakut T,Tunali A

更新日期：2005-08-01 00:00:00

abstract：BACKGROUND:Chronic Myeloid Leukemia (CML) is characterized by the overproduction of BCR-ABL, a tyrosine kinase with constitutive activity, in which the majority of CML patients have e13a2 or e14a2 transcripts. Reckoned the possible associations between the hematologic and molecular features of the disease, a profound u...

journal_title：Leukemia research

authors： Ghalesardi OK,Khosravi A,Azizi E,Ahmadi SE,Hajifathali A,Bonakchi H,Shahidi M

更新日期：2021-01-19 00:00:00

abstract：:The basis of intrinsic resistance of blasts from patients with acute non-lymphocytic leukemia (ANLL) to methotrexate was studied. MTX polyglutamate formation was measured in blast cells from 19 patients with ANLL and in 7 pediatric patients with acute lymphocytic leukemia (ALL), after in vitro incubation for 24 h with...

journal_title：Leukemia research

authors： Lin JT,Tong WP,Trippett TM,Niedzwiecki D,Tao Y,Tan C,Steinherz P,Schweitzer BI,Bertino JR

更新日期：1991-01-01 00:00:00

abstract：:A novel bivalent single chain fusion protein, Bic3, was assembled consisting of the catalytic and translocation domains of diphtheria toxin (DT(390)) fused to two repeating sFv molecules recognizing human CD3 epsilon of the human T-cell receptor. Historically, problems with these constructs include low yield, toxicity...

journal_title：Leukemia research

authors： Vallera DA,Todhunter D,Kuroki DW,Shu Y,Sicheneder A,Panoskaltsis-Mortari A,Vallera VD,Chen H

更新日期：2005-03-01 00:00:00

abstract：:We have previously shown that forced expression of the transcription factor Scl in WEHI-3B D(+) cells prevents ATRA-induced cell differentiation. We now find that the overexpression of Rbtn2 also interferes with induction of differentiation by ATRA. Addition of LiCl to ATRA treatment restored the capacity of both Scl-...

journal_title：Leukemia research

authors： Rice AM,Li J,Sartorelli AC

更新日期：2004-04-01 00:00:00

abstract：:The prognostic effect of hypogammaglobulinemia (HGG), clinical and biologic characteristics on the infection risk and outcome has been retrospectively analyzed in 899 patients with stage A chronic lymphocytic leukemia (CLL). Low levels of IgG were recorded in 19.9% of patients at presentation, low levels of IgM and/or...

journal_title：Leukemia research

authors： Mauro FR,Morabito F,Vincelli ID,Petrucci L,Campanelli M,Salaroli A,Uccello G,Petrungaro A,Ronco F,Raponi S,Nanni M,Neri A,Ferrarini M,Guarini AR,Foà R,Gentile M

更新日期：2017-06-01 00:00:00

abstract：:The surface marker phenotype of lymphocytes derived from 12 patients with B-CLL was compared to that of lymphocytes from 10 patients with an other monoclonal but clinical benign form of B-cell proliferative disorder termed monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS). A panel of well character...

journal_title：Leukemia research

authors： Garcia C,Rosén A,Kimby E,Aguilar-Santelises M,Jondal M,Bjorkholm M,Holm G,Mellstedt H

更新日期：1989-01-01 00:00:00

abstract：:The genes for the CDK4/6-inhibitors p16INK4A/MTS1 and p15INK4B/MTS2 are frequently deleted in hematological malignancies. A new member of this family of CDK4/6 inhibitors is p18. In order to assess p18 growth-suppressor gene alterations in hematological neoplasms, we investigated 31 lymphoma and leukemia cell lines by...

journal_title：Leukemia research

authors： Siebert R,Willers CP,Fosså A,Kloke O,Nowrousian MR,Seeber S,Opalka B

更新日期：1996-02-01 00:00:00

abstract：:CD200, a membrane glycoprotein of the immunoglobulin superfamily, is overexpressed in CLL. Soluble in serum CD200 (sCD200) is correlated with poor prognosis in CLL. ADAM (a disintegrin and metalloproteinase) enzymes are implicated in membrane protein shedding. ADAM28 mRNA expression in CLL was correlated with plasma s...

journal_title：Leukemia research

authors： Twito T,Chen Z,Khatri I,Wong K,Spaner D,Gorczynski R

更新日期：2013-07-01 00:00:00

abstract：:Argininosuccinate synthetase (ASS) is a ATP-dependent and rate-limiting enzyme of the urea cycle which catalyzes L-citrulline to L-arginine in combination with argininosuccinate lyase (ASL). We demonstrate here that (a) human normal T and B lymphocytes did not express ASS activity, (b) however, three adult T leukemia ...

journal_title：Leukemia research

authors： Sugimura K,Kimura T,Arakawa H,Ohno T,Wada Y,Kimura Y,Saheki T,Azuma I

更新日期：1990-01-01 00:00:00

abstract：:Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristin...

journal_title：Leukemia research

authors： Miyashita K,Tomita N,Taguri M,Suzuki T,Ishiyama Y,Ishii Y,Nakajima Y,Numata A,Hattori Y,Yamamoto W,Miyazaki T,Tachibana T,Takasaki H,Matsumoto K,Hashimoto C,Takemura S,Yamazaki E,Fujimaki K,Sakai R,Motomura S,Ishi

更新日期：2015-08-29 00:00:00

abstract：:N-Propyl-N-nitrosourea (PNU) was proved to be a strong leukemogen, which induces myelogenous leukemia or thymic lymphoma in rats. BUF/Mna rats and F344 rats were the strain most susceptible to thymic lymphomagenic activity of PNU. In addition, F1 rats between BUF/Mna and WKY rats were also susceptible to PNU-lymphomag...

journal_title：Leukemia research

authors： Ogiu T,Utsumi KR,Fukami H,Matsuyama M

更新日期：1988-01-01 00:00:00

abstract：:In a recent phase I study, a combination of gemcitabine at 10 mg/(m(2)min) for 12 h and mitoxantrone 12 mg/m(2) daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refrac...

journal_title：Leukemia research

authors： Apostolidou E,Estey E,Cortes J,Garcia-Manero G,Faderl S,Thomas D,Tsimberidou A,Kantarjian H,Giles FJ

更新日期：2003-04-01 00:00:00

abstract：:The study was undertaken to elucidate the regulatory roles of GMP reductase (GMPR) and IMP dehydrogenase (IMPDH) on purine interconversion during differentiation. Treatment of HL-60 cells with retinoic acid (1 microM) induced granulocytic differentiation which was accompanied with a 2.4-fold increase in GMPR and 55% d...

journal_title：Leukemia research

authors： Nakamura H,Natsumeda Y,Nagai M,Takahara J,Irino S,Weber G

更新日期：1992-06-01 00:00:00

abstract：:The use of low density lipoprotein (LDL) as drug carrier in acute myeloblastic leukemia chemotherapy is attractive due to high LDL uptake by leukemic cells. Lipid-based formulations, such as liposomes or microemulsions are promising alternatives. In the current study, we incorporated N-trifluoroacetyl-adriamycin-14-va...

journal_title：Leukemia research

authors： Masquelier M,Lundberg B,Peterson C,Vitols S

更新日期：2006-02-01 00:00:00

abstract：:A retrospective cytogenetic study was performed to determine whether non-random chromosome aberrations were related to the outcome of marrow transplantation for advanced stage acute leukemia (AL) and chronic myelogenous leukemia (CML). The patients were registered on SWOG-8612, a randomized comparison of busulphan and...

journal_title：Leukemia research

authors： Slovak ML,Kopecky KJ,Wolman SR,Henslee-Downey JP,Appelbaum FR,Forman SJ,Blume KG

更新日期：1995-06-01 00:00:00

abstract：:TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. Lower TCL-1 levels w...

journal_title：Leukemia research

authors： Browning RL,Geyer SM,Johnson AJ,Jelinek DF,Tschumper RC,Call TG,Shanafelt TD,Zent CS,Bone ND,Dewald GW,Lin TS,Heerema NA,Grever MR,Kay NE,Byrd JC,Lucas DM

更新日期：2007-12-01 00:00:00

abstract：:High CD23 expression is a hallmark of B-CLL cells. It is lost during in vitro culture and can be reinduced by IL-4, albeit to a lower extent than in normal B cells. To elucidate the events controlling CD23 expression in B-CLL cells, the IL-4 mediated induction of STAT6 was investigated. Western-blot analysis demonstra...

journal_title：Leukemia research

authors： Kneitz C,Goller M,Seggewiss R,Yaman A,Serfling E,Tony HP

更新日期：2000-04-01 00:00:00

abstract：:The etiology of LGL leukemia is not known; however, we recently detected HTLV-II in a patient with LGL leukemia. In this study, we found that sera from 6 of 28 patients with LGL leukemia were positive for HTLV-I/II using a whole virus ELISA; moreover, the ELISA-negative sera were near the positive cut-off value. There...

journal_title：Leukemia research

authors： Loughran TP Jr,Sherman MP,Ruscetti FW,Frey S,Coyle T,Montagna RA,Jones B,Starkebaum G,Poiesz BJ

更新日期：1994-06-01 00:00:00

abstract：:While critical steps in the regulation of leukemia cell development have been intensively studied in recent years, less is known about the interactions of leukemic cells with their stroma. Previously, we have shown that human acute myeloid leukemia (AML) cells differentiate upon injection into murine blastocysts. We h...

journal_title：Leukemia research

authors： Pramanik K,Trüpschuch S,Greiner A,Ruthardt M,Henschler R,Müller AM

更新日期：2008-05-01 00:00:00

abstract：:Expression of cell cycle-regulating genes was studied in human myeloid leukemia cell lines ML-1, ML-2 and ML-3 during induction of differentiation in vitro. Myelomonocytic differentiation was induced by phorbol ester (12-o-Tetradecanoyl-phorbol-13-acetate, TPA), tumor necrosis factor alpha (TNFalpha) or interferon gam...

journal_title：Leukemia research

authors： Ullmannová V,Stöckbauer P,Hradcová M,Soucek J,Haskovec C

更新日期：2003-12-01 00:00:00

abstract：:Imatinib is a tyrosine kinase inhibitor and is now used regularly in chronic myeloid leukaemia therapy in chronic phase with great success. This drug due its very nature of action is suspected to be teratogenic hence the patients are counseled not to get pregnant while on this drug. However in world literature few nor...

journal_title：Leukemia research

authors： Meera V,Jijina F,Shrikande M,Madkaikar M,Ghosh K

更新日期：2008-10-01 00:00:00

abstract：:Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients who are resistant to imatinib are commonly treated with second-generation tyrosine kinase inhibitors (TKIs). Limited data exist on the possible effects of these drugs on subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT).The outco...

journal_title：Leukemia research

authors： Breccia M,Palandri F,Iori AP,Colaci E,Latagliata R,Castagnetti F,Torelli GF,Usai S,Valle V,Martinelli G,Rosti G,Foà R,Baccarani M,Alimena G

更新日期：2010-02-01 00:00:00

abstract：:ABCG2 encodes a transporter protein that is associated with multidrug-resistant phenotypes in many cancers, including acute myeloid leukemia (AML); high levels of expression are generally associated with a poor prognosis. To better understand how expression of ABCG2 is controlled in pediatric AML, we performed a detai...

journal_title：Leukemia research

authors： Campbell PK,Zong Y,Yang S,Zhou S,Rubnitz JE,Sorrentino BP

更新日期：2011-10-01 00:00:00

abstract：:CD200 is a relatively ubiquitously expressed molecule that plays a role in cancer immune evasion through interaction with its receptors. High expression levels of CD200 have been described in different human malignancies. For example, CD200 has been shown to be targeted after RAS/RAF/MEK/ERK activation in melanoma. He...

journal_title：Leukemia research

authors： Conticello C,Giuffrida R,Parrinello N,Buccheri S,Adamo L,Sciuto MR,Colarossi C,Aiello E,Chiarenza A,Romano A,Salomone E,Gulisano M,Giustolisi R,Di Raimondo F

更新日期：2013-12-01 00:00:00

abstract：:Accumulation of cytosine arabinoside triphosphate (araCTP) from a range of cytosine arabinoside (araC) concentrations (1-50 microM) was measured during incubations of leukemic cells freshly isolated from patients with acute leukemia. In all but one patient, increments in extracellular araC above 10 microM did not incr...

journal_title：Leukemia research

authors： Jamieson GP,Snook MB,Wiley JS

更新日期：1990-01-01 00:00:00

abstract：:We evaluated the efficacy of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (CAG) in elderly patients with previously untreated acute myeloid leukemia. Patients aged between 60 and 70 years who were not eligible for standard chemotherapy protocols and patients aged over 70 year...

journal_title：Leukemia research

authors： Suzushima H,Wada N,Yamasaki H,Eto K,Shimomura T,Kugimiya MH,Horikawa K,Nishimura S,Tsuda H,Mitsuya H,Asou N

更新日期：2010-05-01 00:00:00

abstract：:During 2004-2006, two hypomethylating agents (HMAs) were approved for the treatment of myelodysplastic syndromes (MDS) in the United States. We assessed the impact of HMAs on the cost of care and survival of MDS patients, by constructing a cohort of patients who were diagnosed during 2001-2007 (n=6556, age ≥66.5 years...

journal_title：Leukemia research

authors： Wang R,Gross CP,Frick K,Xu X,Long J,Raza A,Galili N,Zikria J,Guan Y,Ma X

更新日期：2012-11-01 00:00:00

abstract：:This paper reports the results of a case control study of non-Hodgkin's lymphoma in the Yorkshire Health Region. In all, 437 cases and 724 controls were interviewed. Risk factors associated with past skin conditions, family history of cancer and infectious mononucleosis, aspects of social life and contact with wood du...

journal_title：Leukemia research

authors： Cartwright RA,McKinney PA,O'Brien C,Richards ID,Roberts B,Lauder I,Darwin CM,Bernard SM,Bird CC

更新日期：1988-01-01 00:00:00

abstract：:This study was aimed to illustrate the significance of minimal residual disease (MRD) assessment on day 22 in childhood acute lymphoblastic leukemia. MRD were measured on day 22, day 36, week 12, month 6 and month 12 by four-color flow cytometry. The 5-year cumulative incidence of relapse was significantly different f...

journal_title：Leukemia research

authors： Xu XJ,Tang YM,Shen HQ,Song H,Yang SL,Shi SW,Xu WQ

更新日期：2012-08-01 00:00:00